Share Issue News

NEW YORK--(BUSINESS WIRE)--Schrödinger, Inc. (Nasdaq: SDGR) today reported that on March 14, 2026, the company granted (i) a non-statutory stock option to purchase 1,950 shares of the company’s common stock to one newly hired employee and (ii) restricted stock units (RSUs) with respect to 4,375 shares of the company’s common stock to two newly hired employees. These grants were made pursuant to the company’s 2021 Inducement Equity Incentive Plan, were approved by the compensation committee of t...

BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine and has a lead investigational medicine, zorevunersen, in development as a first-in-class potential disease-modifying treatment for Dravet syndrome. The Company today announced that, effective on March 16, 2026, it granted stock options to purchase an aggregate of 58,650 shares of common stock to six ne...

DALLAS--(BUSINESS WIRE)--Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company focused on developing FB102, which is a proprietary anti-CD122 monoclonal antibody therapeutic candidate with potentially broad autoimmune and autoimmune-related indications, today announced the issuance of equity inducement awards as required by the Nasdaq Stock Market Rules. In accordance with NASDAQ Listing Rule 5635(c)(4), the Compensation Committee of Forte’s Boa...

BOSTON--(BUSINESS WIRE)--Sensei Biotherapeutics, Inc. (Nasdaq: SNSE) today announced that, effective on March 11, 2026, Sensei’s Board of Directors granted a new employee an option to purchase 166,435 shares of the Company’s common stock in connection with their employment (collectively, the “Option Award”). The Option Award was granted as an inducement material to the individual entering employment with Sensei in accordance with Nasdaq Listing Rule 5635(c)(4). The Option Award has an exercise...

NEW YORK--(BUSINESS WIRE)--Metropolitan Bank Holding Corp. (the “Company”) (NYSE: MCB), the holding company for Metropolitan Commercial Bank (the “Bank”), today announced the underwriters for its recently completed public offering of common stock have exercised a portion of their overallotment option and completed the sale of an additional 213,395 shares of common stock at the public offering price of $85.00 per share. The expected proceeds to the Company in connection with the exercise of the...

MIDLAND, Texas--(BUSINESS WIRE)--New Era Energy & Digital, Inc. (Nasdaq: NUAI) (“New Era” or the “Company”), a developer and operator of next-generation digital infrastructure and integrated power assets in the Permian Basin, today announced the appointment of Ted Warner as Chief Financial Officer, effective March 16, 2026. Mr. Warner brings nearly 20 years of experience across energy, power, and digital infrastructure capital markets, including investment banking and executive leadership r...

SAN FRANCISCO--(BUSINESS WIRE)--Chegg, Inc. (NYSE:CHGG), a global learning company, today announced that on March 13, 2026 (“Grant Date”), its Compensation Committee granted equity awards pursuant to the Chegg 2023 Equity Inducement Plan (the “Plan”). One newly hired employee received a grant of restricted stock units (“RSUs”) representing 150,000 shares of Chegg common stock (“Shares”) in reliance on the employment inducement award exception to New York Stock Exchange Listing Rule 303A.08. The...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK; the “Company”) today announced that the company granted inducement equity awards covering an aggregate of 60,655 shares of its common stock to five newly hired employees, consisting of inducement stock options to purchase an aggregate of 24,506 shares of common stock and inducement restricted stock units, covering an aggregate of 36,149 shares of its common stock. The awards are subject to all terms and conditions and other provisio...

SAN DIEGO--(BUSINESS WIRE)--Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation and immunology (NI&I) indications, today announced that on March 12, 2026 (Grant Date), the Compensation Committee of the Company’s Board of Directors granted an inducement award consisting of a non-qualified stock option to purchase 51,000 shares of Class A common st...

BRANFORD, Conn.--(BUSINESS WIRE)--Quantum-Si Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)...